PHARMACOKINETIC, PHARMACODYNAMIC, AND CLINICAL ASSESSMENTS USED TO SELECT THE RECOMMENDED PHASE 2 DOSE AND SCHEDULE OF SELINEXOR IN NON-HODGKIN LYMPHOMA (NHL)/DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
EHA Library, Yosef Landesman,
298134
NIVOLUMAB-BASED IMMUNOTHERAPY IN RELAPSED/REFRACTORY B-CELL LYMPHOMA, UNCLASSIFIABLE, WITH FEATURES INTERMEDIATE BETWEEN DIFFUSE LARGE B-CELL LYMPHOMA AND CLASSICAL HODGKIN LYMPHOMA
EHA Library, Olesia Smykova,
298142
CLINICAL CHARACTERISTICS, PROGNOSTIC FACTORS AND TREATMENT OUTCOMES OF PATIENTS WITH PLASMABLASTIC LYMPHOMA: RETROSPECTIVE ANALYSIS OF KROHEM, THE CROATIAN COOPERATIVE GROUP FOR HEMATOLOGICAL DISEASES
EHA Library, Dino Dujmovic,
298148
POLARGO: RANDOMIZED PHASE III STUDY OF POLATUZUMAB VEDOTIN PLUS RITUXIMAB, GEMCITABINE, AND OXALIPLATIN (R-GEMOX) IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)
EHA Library, Juan-Manuel Sancho,
298149
FREQUENCY, CLINICAL FINDINGS, RISK FACTORS, TREATMENT AND FOLLOW-UP OF CYTOMEGALOVIRUS INFECTION IN PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS
EHA Library, Hale Oren,
298233